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Abstract
Preimplantation genetic diagnosis (PGD) is a powerful tool to tackle the transmission of monogenic inherited
disorders in families carrying the diseases from generation to generation. It currently remains a challenging task,
despite PGD having been developed over 25 years ago. The major difficulty is it does not have an easy and general
formula for all mutations. Different gene locus needs individualized, customized design to make the diagnosis
accurate enough to be applied on PGD, in which the quantity of DNA is scanty, whereas timely laboratory
diagnosis is mandatory if fresh embryo transfer is desired occasionally. Indicators for outcome assessment of a
successful PGD program include the successful diagnosis rate on blastomeres (Day 3 cleavage-stage embryo
biopsy) or trophectoderm cells (Day 5/6 blastocyst biopsy), the implantation rate per embryo transferred, and
the livebirth rate per oocyte retrieval cycle. Hemophilia A (HA) is an X-linked recessive bleeding disorder caused
by various types of pathological defects in the factor VIII gene (F8). The mutation spectrum of the F8 is complex,
according to our previous report, including large segmental intra-gene inversions, large segmental deletions
spanning a few exons, point mutations, and total deletion caused by chromosomal structural rearrangements.
In this review, the molecular methodologies used to tackle different mutants of the F8 in the PGD of HA are to
be explained, and the experiences of successful use of amplification refractory mutation system-quantitative
polymerase chain reaction (ARMS-qPCR) and linkage analysis for PGD of HA in our laboratory are also provided.
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Background
Preimplantation genetic diagnosis (PGD) had become a
standard of care when dealing with stopping the trans-
mission of the heritable disease from generation to gen-
eration since it was firstly introduced in 1990 [1, 2]. The
gold standard of molecular technology used for PGD
nowadays is the coamplification of the polymorphic
microsatellite linkage markers [3, 4]. However, such
techniques cannot avoid the possibility of recombination
occurred within the segment which separated the linked
polymorphic markers and the disease loci, and it is
advised to combine more informative linkage markers to
reduce the chance of misdiagnosis. On the other hand,
direct mutation detection assay, either rapid PCR-based
or the more time-consuming sequencing-based genotyp-
ing platforms, is prone to allele dropout (ADO), which
may ensue a catastrophic false-negative misdiagnosis in
PGD of autosomal dominant monogenic disorder [4, 5].
Hemophilia A (HA) (OMIM 306700), a bleeding
disorder which causes long-term disability, is a X-linked
recessive disorder and its causative gene is situated at
Xq28, the factor VIII (F8) gene, is a serious threat for
public health in Taiwan, and we had first published its
mutation spectrum in the Taiwanese population in 2008
[6]. The mutation spectrum included rearrangements
such as intron 1 inversions (INV1) and intron 22 inver-
sions (INV22), large deletions spanning for consecutive
exons, small deletions involving only a few base pairs,
and point mutations [6]. The broad spectra of F8 muta-
tions have also been reported in several other studies
[7–9]. The genotyping itself for the F8 is already a
daunting task given its complicated existing mutations
patterns, let alone the PGD. In spite of the challenges,
we managed to tackle these difficulties in a few families
who came to our hospital seeking for PGD. Meanwhile,
a few similar efforts had been reported from other la-
boratories [10, 11], which indicates PGD for HA is feas-
ible, at least in those families the mutation has been
confirmed. Here we will give a concise review of PGD
for HA, including the different molecular technologies
used to tackle different mutation patterns, and also to
cite a few of our experience with successful outcome,
that is, to give birth to normal unaffected babies in
families suffered from HA.
Review
Mutation spectrum of the F8 gene, genotyping strategies,
and possible PGD approaches
Since the publication of the sequence of the F8 in 1984,
more than 2000 gene mutations causing HA have been
described and these are catalogued in the Human Gene
Mutation Database (HGMD; http://www.hgmd.cf.ac.uk/
ac/index.php) and Factor VIII Variant Database (http://
www.factorviii-db.org/). In 2008, we had first published
the mutation spectrum in the Taiwanese population [6].
Of 31 unrelated HA patients (19 severe and 10 moder-
ate/mild males, and 2 severe females), 12 (38.7 %) and 1
(3.2 %) severe males were genotyped with INV22 and
INV1 respectively. The F8 defects in the remaining 18
inversion-negative patients cover a wide spectrum, in
which 17 different mutations were identified (10 mis-
sense and 3 nonsense mutations, and 2 small and 2 large
deletions). Eleven of these mutations are novel and
unique, confirming a high diversity of molecular defects
in HA [6]. A systematic review for data from 30 studies
on 5383 patients had been reported and showed 45 % of
HA had INV22, 2 % INV1, 3 % large deletions, 16 %
small deletions or insertions, and 28 % point mutations
(15 % missense mutations, 10 % nonsense mutations,
and 3 % splicing site mutations). In 4.6 % of patients, the
mutation was unknown [12]. Overall, with the excep-
tions of recurrent INV22 and INV1, no mutation hot
spots have been identified.
There are a number of different approaches for the
genotyping of HA (Table 1). For reasons of rapid and
smart screening, however, targeted mutation analysis for
the recurrent INV22 and INV1 has become the first test
assessed in patients (particularly in severely affected he-
mophiliacs). INV22 can be detected by Southern blotting
or, more time- and labor-saving choice, by long-distance
polymerase chain reaction (long-distance PCR) or inverse
PCR (I-PCR) [13, 14]. INV1 is typically detected by multi-
plex PCR [15]. Other mutations responsible for HA are
mostly point mutation and small deletion/insertion in the
F8 gene and their spectrum is quite complex. In these
cases, mutation can be detected by PCR with a number of
screening methods (e.g., single strand conformational
polymorphism, conformation sensitive gel electrophoresis,
amplification and mismatch detection, denaturing gradi-
ent gel electrophoresis) followed by direct DNA sequen-
cing [16–21]. For female patients with only one mutation
detected and also in those females suspected to be carriers
but no mutation could be found, gene dosage assays such
as multiplex ligation-dependent probe amplification
(MLPA) should be applied to screen for the underlying
exon deletions since deletions in single allele usually es-
cape detection by the PCR-based analysis, due to the
masking of the non-deleted allele. In Fig. 1, we exemplified
the MLPA finding of a female HA patient who was karyo-
typed as 45,X [22]/46,X,idic(X)(q21) [8] mosaicism. Her
aberrant X-chromosome (idic(X)(q21)) do not contain the
Xq22q28 (and thus F8 gene) and familiar follow-up stud-
ies demonstrate this anomaly is of de novo. PCR amplifica-
tion for exon1-22 of the F8 is failure in patient but is
successful in her parents. Through the MLPA analyses, it
is evidenced that the patient carries an exon 1–22 deletion
in the allele on her “morphologically-normal” X-
chromosome, which is inherited from her mother (Fig. 1).
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Table 1 Genotype-phenotype relationship, genetic testing and preimplantation genetic diagnosis (PGD) in hemophilia A







Severe • I-PCR (for INV22)
• Long-distance PCR (for INV22)
• Southern blotting (for INV22)











• Mild, Moderate (majority)
• Severe (majority)
• Severe (majority)
Direct DNA sequencing • ARMS-qPCR
• Linkage analysis
Small deletion/insertion (<1 exon) 16 % Severe (majority) Direct DNA sequencing • ARMS-qPCR
• Linkage analysis
Large deletion (≥1 exon) 3 % Severe (majority) MLPA • Linkage analysis
Others (e.g., Complex rearrangement) NA Severe (majority) Depending on mutation entities • Linkage analysis
MLPA multiplex ligation-dependent probe amplification, I-PCR inverse polymerase chain reaction, ARMS amplification refractory mutation system, NA not available
aSee the review in Gouw et al., [12]
bHA patients are clinically divided into three different severities based on the residual FVIII coagulant activity (FVIII:C): severe (FVIII:C < 1 % of normal level),
moderate (FVIII:C is 1–5 % of normal level) and mild (FVIII:C is 5–30 % of normal level)
Fig. 1 Genetic testing for a female patient (indicated by an arrow) with severe hemophilia A. a Cytogenetic analysis identifies a 45,X [22]/46,X,idic(X)(q21)
[8] mosaicism, indicating at least one F8 allele loss. b MLPA analysis for the F8 gene of the patient detects only copy of exon 23–26 peaks indicating an
exon 1–22 deletion in the allele on her “morphologically-normal” X-chromosome. MLPA for the patient’s mother detects about 1/2 DNA dosage of
exon1-22 indicating a carrier of exon 1–22 deletion. Arabic numbers, the exon numbers of the F8 gene. “c”, the internal controls used in MLPA. “?”, an
unexpectedly amplified peck which is not illustrated in the instruction of the MLPA FVIII kit, SALSA P178. “*”, loss of one copy in exons. “▼”, loss of two
copies in exons
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Given the marked morbidity associated with severe
HA, PGD has become a feasible option for couples at
risk of having a child with HA since it reduces the risk
of termination of affected pregnancies. Gender selection
by fluorescence in situ hybridization (FISH) and transfer
of only female embryos is a simple strategy for X-linked
recessive disorders, such as HA, and has been adopted
in many clinics [11]. However, in practice, gender se-
lection is illegal in some countries (e.g., Taiwan) and
methods allowing the correct and more definitive diag-
nosis of the HA status of every embryo are more desir-
able because the number of embryos available for
transfer is increased. PGD involving whole genome amp-
lification (WGA) step was broadly applied to mutation
detection strategies, but the high rate of amplification
bias renders WGA an imperfect option [22]. Recently,
co-amplification of polymorphic microsatellite markers,
linked with the targeted mutation, had been the gold-
standard genotyping strategy for PGD [4, 23–26]
(Table 1). A linkage approach using polymorphic
markers located near the mutation allows monitoring
the occurrence of allele dropout, a known problem
associated with PCR amplification bias in PGD. Below,
we describe our experience with two HA families seek-
ing for PGD.
Experience of PGD of hemophilia A in our laboratory
Two Taiwanese couples were referred to our center for
PGD of HA. Preliminary genetic testing of F8 for two
couples showed the two wives are both HA carriers: one
has a splicing site mutation, c.1538-1G > A, and the
other has a common INV22. For the family with c.1538-
1G > A mutation, an in-house developed duplex-nested
ARMS-qPCR was customized designed for PGD [4, 5].
The optimized PGD protocol was then performed to de-
tect the disease-causing mutation in embryos acquired
after ovarian stimulation. Seven single blastomeres biop-
sied from corresponding day-3 (8-cell cleavage-stage)
embryos were collected and examined independently in
a sterile PCR tube. Each blastomere cell was lysed with
125 μg/mL proteinase K at 50 °C for 60 min and inacti-
vated at 99 °C for 4 min. Duplex-nested PCR was then
used to amplify the intron 10–11 region of F8 gene,
which includes the targeted mutation. The two primer
sets, designed based on the reverse strand’s F8 gene
sequence, were OF: CTGAGGACCCATTACCCTGA
and OR: CCTGCAACAGTGCTACATGC for the first
PCR (amplicon size: 937 bp), and IF: CTTGCTCC
CTTTCCTCACAG and IR: TGGGGAGGATCAGCTA-
GAGA for the secondary PCR (amplicon size: 757 bp)
(Fig. 2a). The first PCR was carried out in a 40 μL reac-
tion, consisting of 1X PCR buffer, 1.25 mmol/L MgCl2,
0.35 mmol/L dNTP, each 0.5 μmol/L of OF and OR
primer, 1X GC-RICH solution, and 1U Faststart Taq
DNA polymerase (Roche Diagnostics GmbH, Mannheim,
Germany). The cycling conditions were 95 °C, 5 min,
followed by 25 cycles of 95 °C, 30 s, 55 °C, 30 s and
71 °C, 1 min, and a final extension at 71 °C, 2 min. The
PCR products were directly subjected to the second
round of PCR by adding 10 μL PCR supplement with a
similar PCR mixture to that used in the first PCR, ex-
cept for the primer set (IF and IR). Cycling conditions
were similar to the first PCR, but the number of cycles
in the second step was increased from 25 to 40. To en-
sure an accuracy of the PCR, amplified fragments were
confirmed by direct sequencing. For ARMS-qPCR, two
sequence-specific forward primers, modified with a
mismatch at the penultimate nucleotide position of the
mutation site to increase the specificity of the reaction,
were designed: (MUF: TATGGTTTTGCTTGTGGGT
GA for the mutant allele and WTF: TATGGTTTT
GCTTGTGGGTGG for the wild-type allele). The two
forward primers were respectively paired with the same
reverse primer 3rdR: TGAGGAGAGGGCCAATGAGT
(amplicon size:198 bp) (Fig. 2b). The ARMS-qPCR per-
formed on the LightCycler 480 Real-Time PCR System
(Roche, Mannheim, Germany) in a 20 μL reaction, con-
sisted of 0.5 ng of the duplex-nested PCR product,
0.5 μmol/L of each primer, 1X SYBR Green PCR
Master Mix (Finnzymes, Espoo, Finland). Cycling con-
ditions were: 95 °C, 10 min, followed by 45 cycles at
95 °C, 10 s, 60 °C and 60 s. The exemplified results of
ARMS-qPCR were shown in Fig. 2c. Of the seven
blastomeres examined, two were reported as affected
embryos with the homo- or hemizygous c.1538-1G > A
mutation, one was known as a heterozygous carrier,
and the remaining four were presented as same as wild-
type pattern without the mutation. However, only one
unaffected embryo kept good morphology and was
transferred on day 5. After 39 weeks of uneventful
gestation, one healthy baby girl was born successfully
with a birth weight of 3040 g. Postnatal genotyping
confirmed the girl to be an unaffected carrier and,
interestingly, she was HLA-compatible with her older
brother affected by HA (see family 1 in Fig. 3).
The INV22 of F8 is one of the most frequent cause of
severe HA, known as a result of homologous recombin-
ation between the int22h-1 region within the F8 locus
and either int22h-2 (Inv22 type II) or int22h-3 (Inv22
type I), which lie nearly 400 kb distal to F8 [27]. The
gene rearrangements tend to increase the difficulty of
PGD experimental design performed in the affected fam-
ilies. In the second PGD family with F8 INV22 mutation,
the couple (2–1 and 2–2) has had a healthy boy and they
would like to get more babies without HA. We per-
formed 3 PGD cycles of HA during the period of Sep.
2014 to Dec. 2015 using short tandem repeat (STR)
markers and capillary electrophoresis for direct linkage
The Author(s) Thrombosis Journal 2016, 14(Suppl 1):33 Page 82 of 163
analysis. Five informative STR markers distributed
within or near the flanking region of the F8 were
selected for PGD performing (see family 2 in Fig. 3).
Among a total of 19 examined embryos, 5 wild types
and 4 INV22 carriers were selected and transferred dur-
ing the period. Unfortunately, pregnancy outcome did
not occur as expected, possibly due to ad maternal age,
embryo morphology, development and other abnormal-
ities. Despite the fact that no pregnancy was achieved in
the PGD experience so far, they are still willing to keep
trying.
Discussion
The outcome indicators of PGD can be classified as suc-
cessful diagnosis rate (the number of embryos which
diagnosis was made/the total number of embryos being
biopsied), implantation rate (the number of embryos im-
planted/the total number of embryos being transferred),
and the live-birth rate (the rate of liveborn pregnancy
per transferred cycle or the rate of liveborn pregnancy
per oocyte-retrieval). It is now still under debate whether
frozen or fresh embryo transfer can achieve a better out-
come against the other. However, it is vitally important
that PGD laboratories developed a timely genotyping
platform to cope with the need of fresh embryo transfer,
especially when Day 5/6 blastocyst biopsy is undertaken.
For rapid PGD of HA, the direct mutation detection,
e.g., ARMS-qPCR, can greatly increase the reliability of
mutation detection in embryos with small insertions/
deletion and point mutations (see the exemplified
Fig. 2 Schematic diagram of a duplex-nested ARMS-qPCR for PGD of a splicing-site point mutation, located at the junction of intron 10 and exon 11
of F8, c.1538-1G > A (bold letter). a Primers for duplex-nested PCR were first designed to amplify the region covering the position of the mutation. OF
and OR indicate the outer primer set, and IF and IR indicate inner primer set. b Primers specific for the amplification of the wild-type (WT) and mutant
(MU) alleles, respectively, were subsequently used for ARMS-qPCR where the duplex-nested PCR amplicon was used as DNA template. c Representative
ARMS-qPCR results for wild-type control (homozygous WT/WT or hemizygous WT), female carrier (heterozygous WT/MU), and affected male individual
(hemizygous MU)
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couple 1). However, for large and complex F8 defects, e.g.,
INV1 and INV22, PGD by direct genotyping is not easily
feasible and indirect linkage analysis with informative
markers may be considered (see the exemplified couple 2).
Of noted, the chance of recombination between the
markers and mutation can lead to small diagnostic error
Fig. 3 Exemplified PGD of F8 defects for two hemophilia A families: family 1 (c.1538-1G > A mutation) and family 2 (INV22). PGD was performed
using ARMS-qPCR, together with linkage analysis for five informative short tandem repeat (STR) markers ordered from centromere (top) to telomere
(bottom). The numbers in STR markers represent the sizes of PCR amplicons in base pair (bp). In family 1, human leukocyte antigen (HLA) typing with
12 STR markers was also performed. PGD for hemophilia A resulted in a birth of healthy girl (1–4), who was HLA matched to the affected sibling (1–3).
In family 2, PGD for INV22 was directly performed by linkage analysis. The maternal allele linked to INV22 was evidenced by comparing the STR profile
with that of case 2–3 and 2–4. In the pedigree, squares represent males, and circles represent females. Line through, filled, dotted and open the
symbols represent deceased, affected, carrier and unaffected individuals respectively
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and some families may not be informative for any of the
available markers.
Recently, it is noteworthy that because of the popular-
ity of preimplantation genetic screening (PGS), there is a
growing need of concurrent PGD/PGS. At the moment
the strategies used in PGS, if we exclude the outdated
FISH-based diagnostics [28], include array-based (either
array comparative genomic hybridization or single nu-
cleotide polymorphism chromosomal microarray) tech-
niques [29–31], q-PCR based techniques [32, 33], and
next generation sequencing (NGS)-based techniques
[34, 35]. Some of the techniques had been reported to
successfully being applied in PGD combined with PGS
[36–39]. It is inevitable that in the near future, women will
opt for select the unaffected embryos with certain herit-
able monogenic disorders, such as HA, as well as the eu-
ploid embryos which will reduce the chance of abortion
due to aneuploidy in the later gestational period or
improved the implantation rate as many researchers
advocated [40]. However, it will be undisputable only after
more convincing randomized trials to prove the efficacy of
PGS, the combination of PGD and PGS should be offered
to all women underwent PGD [41]. Those couple who
opted for PGD combined with PGS should be counseled
that double selection will inevitable reduce the number of
embryos which are classified as “suitable” for transfer,
thereby reducing all the outcome indicators of PGD, the
most important live-birth rate is certainly included.
Conclusions
PGD of HA by direct mutation analysis or indirect linkage
analysis has become a feasible option for couples at risk of
having an affected child. However, given the broad spectra
of the F8 mutations, genetic counseling along with the
technical aspects of the accuracy and limitations of tests
should be provided for couples who request PGD.
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